Posterior reversible encephalopathy syndrome after anlotinib treatment for small cell lung cancer: A case report and literature review

Anlotinib is an oral multi-targeted tyrosine kinase inhibitor as a third-line and subsequent treatment for patients with small cell lung cancer (SCLC) in China. The neurotoxicity is less reported. Posterior reversible encephalopathy syndrome (PRES) is characterized by headaches, seizures, encephalop...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Xiaomeng, Zhou, Peng, Lv, Wei, Liu, Chuanyong, Liu, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939648/
https://www.ncbi.nlm.nih.gov/pubmed/36814495
http://dx.doi.org/10.3389/fphar.2023.1126235

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939648/
https://www.ncbi.nlm.nih.gov/pubmed/36814495
http://dx.doi.org/10.3389/fphar.2023.1126235

Ejemplares similares